Biologic Exclusivity Provision In USMCA Is Boon To Generics Industry; BIO Is 'Tremendously Worried'
Executive Summary
Revised North American trade deal touted as enabling Congress to address crisis of high drug prices; requirement for 10 years biologic exclusivity is removed and language to allow incentives for generics added.
You may also be interested in...
Generic 'Rewards' Added To, 'Evergreening' Requirements Dropped From North American Trade Deal
USMCA is looking more and more like a win for generic firms, who hope it will be template for future trade agreements.
USCMA Revision Worsens Innovator Woes In Canada
Stripping the revised USMCA deal of provisions to strengthen IP rights for biologics will worsen market difficulties in Canada caused by changes to the drug pricing regime, says industry.
USMCA Trade Negotiations: Could US House Dems' Talks Open Door For AAM Changes?
Biologics exclusivity remains a contentious issue as US Trade Representative and House Democrats begin discussions on the trade pact with Mexico and Canada.